Radiolabeled PSMA-617 Therapy Protocol

PSMA-617 was obtained from ABX GmbH (Radeberg, Germany), and radiolabeling with ¹⁷⁷LuCl₃ was carried out as described in detail before [10 (link), 16 (link)]. Quality control was overseen by experienced radiochemists and physicians with respective training in the field. ¹⁷⁷Lu-PSMA-617 was administered by slow intravenous injection over 30–60 s. Infusion of 1000 mL of saline was initiated 30 min before application at a continuous rate of 300 mL/h. With the intention to limit the uptake to the parotid and submandibular, icepacks were locally applied 30 min before therapy and continued for 1 h [24 (link)]. All therapies were performed as in-patient procedures at our nuclear medicine therapy ward. As mandated by radiation protection legislation, patients remained hospitalized for a minimum 48 h; median hospitalization was 3 (range 2–5) days per cycle.